nodes	percent_of_prediction	percent_of_DWPC	metapath
Paclitaxel—kidney cancer—muscle cancer	0.226	0.509	CtDrD
Paclitaxel—lung cancer—muscle cancer	0.218	0.491	CtDrD
Paclitaxel—TUBB6—Vincristine—muscle cancer	0.0292	0.067	CbGbCtD
Paclitaxel—TUBB8—Vincristine—muscle cancer	0.0292	0.067	CbGbCtD
Paclitaxel—TUBB2B—Vincristine—muscle cancer	0.0292	0.067	CbGbCtD
Paclitaxel—TUBB2A—Vincristine—muscle cancer	0.0292	0.067	CbGbCtD
Paclitaxel—TUBB3—Vincristine—muscle cancer	0.0292	0.067	CbGbCtD
Paclitaxel—TUBB4A—Vincristine—muscle cancer	0.0292	0.067	CbGbCtD
Paclitaxel—TUBB4B—Vincristine—muscle cancer	0.0245	0.056	CbGbCtD
Paclitaxel—TUBB1—Vincristine—muscle cancer	0.0245	0.056	CbGbCtD
Paclitaxel—TUBB—Vincristine—muscle cancer	0.0245	0.056	CbGbCtD
Paclitaxel—ABCC10—Vincristine—muscle cancer	0.0187	0.0428	CbGbCtD
Paclitaxel—ABCC10—Etoposide—muscle cancer	0.0171	0.0392	CbGbCtD
Paclitaxel—ABCC1—Dactinomycin—muscle cancer	0.0117	0.0268	CbGbCtD
Paclitaxel—ABCC10—Doxorubicin—muscle cancer	0.0117	0.0268	CbGbCtD
Paclitaxel—ABCC10—Methotrexate—muscle cancer	0.0113	0.0259	CbGbCtD
Paclitaxel—ABCB11—Vincristine—muscle cancer	0.0102	0.0233	CbGbCtD
Paclitaxel—ABCG2—Dactinomycin—muscle cancer	0.00784	0.018	CbGbCtD
Paclitaxel—ABCC1—Vincristine—muscle cancer	0.00721	0.0165	CbGbCtD
Paclitaxel—ABCC1—Etoposide—muscle cancer	0.00661	0.0151	CbGbCtD
Paclitaxel—CYP1B1—Doxorubicin—muscle cancer	0.00635	0.0145	CbGbCtD
Paclitaxel—ABCB11—Doxorubicin—muscle cancer	0.00635	0.0145	CbGbCtD
Paclitaxel—SLCO1B3—Methotrexate—muscle cancer	0.00632	0.0145	CbGbCtD
Paclitaxel—ABCC2—Vincristine—muscle cancer	0.00534	0.0122	CbGbCtD
Paclitaxel—ABCC2—Etoposide—muscle cancer	0.00489	0.0112	CbGbCtD
Paclitaxel—ABCG2—Vincristine—muscle cancer	0.00483	0.0111	CbGbCtD
Paclitaxel—ABCC1—Doxorubicin—muscle cancer	0.00451	0.0103	CbGbCtD
Paclitaxel—ABCG2—Etoposide—muscle cancer	0.00442	0.0101	CbGbCtD
Paclitaxel—ABCC1—Methotrexate—muscle cancer	0.00437	0.01	CbGbCtD
Paclitaxel—CYP3A7—Vincristine—muscle cancer	0.00357	0.00817	CbGbCtD
Paclitaxel—CYP3A7-CYP3A51P—Vincristine—muscle cancer	0.00357	0.00817	CbGbCtD
Paclitaxel—ABCC2—Doxorubicin—muscle cancer	0.00334	0.00765	CbGbCtD
Paclitaxel—ABCC2—Methotrexate—muscle cancer	0.00323	0.00741	CbGbCtD
Paclitaxel—ABCG2—Doxorubicin—muscle cancer	0.00302	0.00691	CbGbCtD
Paclitaxel—ABCG2—Methotrexate—muscle cancer	0.00292	0.0067	CbGbCtD
Paclitaxel—ABCB1—Dactinomycin—muscle cancer	0.00283	0.00647	CbGbCtD
Paclitaxel—CYP3A5—Vincristine—muscle cancer	0.00267	0.00613	CbGbCtD
Paclitaxel—CYP3A5—Etoposide—muscle cancer	0.00245	0.00561	CbGbCtD
Paclitaxel—CYP2C8—Etoposide—muscle cancer	0.00236	0.0054	CbGbCtD
Paclitaxel—ABCB1—Vincristine—muscle cancer	0.00174	0.00399	CbGbCtD
Paclitaxel—ABCB1—Etoposide—muscle cancer	0.00159	0.00365	CbGbCtD
Paclitaxel—ABCB1—Doxorubicin—muscle cancer	0.00109	0.00249	CbGbCtD
Paclitaxel—ABCB1—Methotrexate—muscle cancer	0.00105	0.00241	CbGbCtD
Paclitaxel—CYP3A4—Vincristine—muscle cancer	0.00104	0.00239	CbGbCtD
Paclitaxel—CYP3A4—Etoposide—muscle cancer	0.000956	0.00219	CbGbCtD
Paclitaxel—TUBB3—Diurnally Regulated Genes with Circadian Orthologs—MYF6—muscle cancer	0.000841	0.0623	CbGpPWpGaD
Paclitaxel—MAP4—embryo—muscle cancer	0.000761	0.0267	CbGeAlD
Paclitaxel—BCL2—TP53 Network—TP73—muscle cancer	0.000683	0.0506	CbGpPWpGaD
Paclitaxel—CYP3A4—Doxorubicin—muscle cancer	0.000652	0.00149	CbGbCtD
Paclitaxel—MAP2—embryo—muscle cancer	0.0006	0.021	CbGeAlD
Paclitaxel—NR1I2—head—muscle cancer	0.000589	0.0207	CbGeAlD
Paclitaxel—BCL2—TP53 Network—TP63—muscle cancer	0.000587	0.0435	CbGpPWpGaD
Paclitaxel—MAP2—Melatonin metabolism and effects—FOXO1—muscle cancer	0.000578	0.0428	CbGpPWpGaD
Paclitaxel—MAP4—renal system—muscle cancer	0.000576	0.0202	CbGeAlD
Paclitaxel—MAPT—tendon—muscle cancer	0.000572	0.02	CbGeAlD
Paclitaxel—TUBB8—head—muscle cancer	0.000565	0.0198	CbGeAlD
Paclitaxel—TUBB8—testis—muscle cancer	0.000546	0.0191	CbGeAlD
Paclitaxel—BCL2—smooth muscle tissue—muscle cancer	0.000544	0.0191	CbGeAlD
Paclitaxel—BCL2—renal system—muscle cancer	0.000524	0.0184	CbGeAlD
Paclitaxel—MAPT—testis—muscle cancer	0.000474	0.0166	CbGeAlD
Paclitaxel—TUBB4A—embryo—muscle cancer	0.000463	0.0162	CbGeAlD
Paclitaxel—MAP4—tendon—muscle cancer	0.00045	0.0158	CbGeAlD
Paclitaxel—TUBB1—bone marrow—muscle cancer	0.000426	0.0149	CbGeAlD
Paclitaxel—BCL2—C-MYB transcription factor network—MYF6—muscle cancer	0.000426	0.0315	CbGpPWpGaD
Paclitaxel—MAP4—vagina—muscle cancer	0.000417	0.0146	CbGeAlD
Paclitaxel—MAP2—cardiac atrium—muscle cancer	0.000406	0.0142	CbGeAlD
Paclitaxel—BCL2—bone marrow—muscle cancer	0.000396	0.0139	CbGeAlD
Paclitaxel—MAP4—head—muscle cancer	0.000386	0.0135	CbGeAlD
Paclitaxel—TUBB3—head—muscle cancer	0.000386	0.0135	CbGeAlD
Paclitaxel—TUBB2A—Signaling events mediated by HDAC Class III—MYOD1—muscle cancer	0.000383	0.0284	CbGpPWpGaD
Paclitaxel—TUBB1—head—muscle cancer	0.000377	0.0132	CbGeAlD
Paclitaxel—TUBB3—testis—muscle cancer	0.000372	0.0131	CbGeAlD
Paclitaxel—MAP4—testis—muscle cancer	0.000372	0.0131	CbGeAlD
Paclitaxel—MAP2—SIDS Susceptibility Pathways—TP73—muscle cancer	0.000368	0.0272	CbGpPWpGaD
Paclitaxel—SLCO1B3—vagina—muscle cancer	0.000365	0.0128	CbGeAlD
Paclitaxel—TUBB1—testis—muscle cancer	0.000364	0.0128	CbGeAlD
Paclitaxel—TUBB4B—embryo—muscle cancer	0.000361	0.0127	CbGeAlD
Paclitaxel—MAPT—BDNF signaling pathway—KIDINS220—muscle cancer	0.00036	0.0266	CbGpPWpGaD
Paclitaxel—MAP2—tendon—muscle cancer	0.000354	0.0124	CbGeAlD
Paclitaxel—TUBB4A—renal system—muscle cancer	0.000351	0.0123	CbGeAlD
Paclitaxel—BCL2—head—muscle cancer	0.00035	0.0123	CbGeAlD
Paclitaxel—TUBB2B—renal system—muscle cancer	0.000339	0.0119	CbGeAlD
Paclitaxel—BCL2—testis—muscle cancer	0.000339	0.0119	CbGeAlD
Paclitaxel—TUBB—smooth muscle tissue—muscle cancer	0.000333	0.0117	CbGeAlD
Paclitaxel—TUBB2A—smooth muscle tissue—muscle cancer	0.000331	0.0116	CbGeAlD
Paclitaxel—MAP2—vagina—muscle cancer	0.000329	0.0115	CbGeAlD
Paclitaxel—TUBB6—smooth muscle tissue—muscle cancer	0.000327	0.0115	CbGeAlD
Paclitaxel—TUBB6—renal system—muscle cancer	0.000315	0.011	CbGeAlD
Paclitaxel—MAP2—head—muscle cancer	0.000304	0.0106	CbGeAlD
Paclitaxel—TUBB2B—cardiac atrium—muscle cancer	0.000304	0.0106	CbGeAlD
Paclitaxel—MAP2—testis—muscle cancer	0.000293	0.0103	CbGeAlD
Paclitaxel—TUBB—cardiac atrium—muscle cancer	0.000287	0.0101	CbGeAlD
Paclitaxel—TUBB2A—cardiac atrium—muscle cancer	0.000286	0.01	CbGeAlD
Paclitaxel—TUBB4B—smooth muscle tissue—muscle cancer	0.000284	0.00996	CbGeAlD
Paclitaxel—TUBB6—cardiac atrium—muscle cancer	0.000282	0.00987	CbGeAlD
Paclitaxel—ABCB11—testis—muscle cancer	0.000281	0.00985	CbGeAlD
Paclitaxel—ABCC10—renal system—muscle cancer	0.000276	0.00965	CbGeAlD
Paclitaxel—TUBB4A—tendon—muscle cancer	0.000274	0.00959	CbGeAlD
Paclitaxel—TUBB4B—renal system—muscle cancer	0.000274	0.00958	CbGeAlD
Paclitaxel—TUBB2B—tendon—muscle cancer	0.000265	0.00927	CbGeAlD
Paclitaxel—TUBB2A—Signaling events mediated by HDAC Class III—FOXO4—muscle cancer	0.00026	0.0193	CbGpPWpGaD
Paclitaxel—TUBB—tendon—muscle cancer	0.00025	0.00877	CbGeAlD
Paclitaxel—TUBB2A—tendon—muscle cancer	0.000249	0.00873	CbGeAlD
Paclitaxel—ABCC10—cardiac atrium—muscle cancer	0.000247	0.00865	CbGeAlD
Paclitaxel—TUBB6—tendon—muscle cancer	0.000246	0.00861	CbGeAlD
Paclitaxel—TUBB2B—vagina—muscle cancer	0.000245	0.0086	CbGeAlD
Paclitaxel—TUBB4B—cardiac atrium—muscle cancer	0.000245	0.00858	CbGeAlD
Paclitaxel—TUBB—bone marrow—muscle cancer	0.000242	0.0085	CbGeAlD
Paclitaxel—TUBB2A—bone marrow—muscle cancer	0.000241	0.00845	CbGeAlD
Paclitaxel—TUBB6—bone marrow—muscle cancer	0.000238	0.00834	CbGeAlD
Paclitaxel—TUBB4A—head—muscle cancer	0.000235	0.00822	CbGeAlD
Paclitaxel—TUBB—vagina—muscle cancer	0.000232	0.00814	CbGeAlD
Paclitaxel—TUBB2A—vagina—muscle cancer	0.000231	0.0081	CbGeAlD
Paclitaxel—TUBB6—vagina—muscle cancer	0.000228	0.00799	CbGeAlD
Paclitaxel—TUBB2B—head—muscle cancer	0.000227	0.00795	CbGeAlD
Paclitaxel—TUBB4A—testis—muscle cancer	0.000227	0.00794	CbGeAlD
Paclitaxel—CYP1B1—smooth muscle tissue—muscle cancer	0.000225	0.00789	CbGeAlD
Paclitaxel—ABCC2—renal system—muscle cancer	0.000221	0.00775	CbGeAlD
Paclitaxel—TUBB2B—testis—muscle cancer	0.000219	0.00768	CbGeAlD
Paclitaxel—CYP1B1—renal system—muscle cancer	0.000217	0.00759	CbGeAlD
Paclitaxel—ABCC10—tendon—muscle cancer	0.000215	0.00754	CbGeAlD
Paclitaxel—TUBB4B—tendon—muscle cancer	0.000214	0.00748	CbGeAlD
Paclitaxel—TUBB2A—head—muscle cancer	0.000213	0.00748	CbGeAlD
Paclitaxel—TUBB6—head—muscle cancer	0.000211	0.00738	CbGeAlD
Paclitaxel—ABCC10—bone marrow—muscle cancer	0.000208	0.0073	CbGeAlD
Paclitaxel—BCL2—Apoptosis—TP73—muscle cancer	0.000208	0.0154	CbGpPWpGaD
Paclitaxel—TUBB—testis—muscle cancer	0.000207	0.00726	CbGeAlD
Paclitaxel—TUBB4B—bone marrow—muscle cancer	0.000207	0.00725	CbGeAlD
Paclitaxel—TUBB2A—testis—muscle cancer	0.000206	0.00723	CbGeAlD
Paclitaxel—TUBB6—testis—muscle cancer	0.000203	0.00713	CbGeAlD
Paclitaxel—MAPT—Copper homeostasis—FOXO1—muscle cancer	0.000203	0.015	CbGpPWpGaD
Paclitaxel—ABCC10—vagina—muscle cancer	0.0002	0.00699	CbGeAlD
Paclitaxel—TUBB4B—vagina—muscle cancer	0.000198	0.00694	CbGeAlD
Paclitaxel—TUBB2A—Signaling events mediated by HDAC Class III—FOXO1—muscle cancer	0.000192	0.0142	CbGpPWpGaD
Paclitaxel—TUBB4B—head—muscle cancer	0.000183	0.00641	CbGeAlD
Paclitaxel—BCL2—Apoptosis—TP63—muscle cancer	0.000179	0.0132	CbGpPWpGaD
Paclitaxel—ABCC10—testis—muscle cancer	0.000178	0.00624	CbGeAlD
Paclitaxel—TUBB4B—testis—muscle cancer	0.000177	0.0062	CbGeAlD
Paclitaxel—ABCC1—cardiac atrium—muscle cancer	0.000175	0.00612	CbGeAlD
Paclitaxel—BCL2—TP53 Network—CDKN2A—muscle cancer	0.000173	0.0128	CbGpPWpGaD
Paclitaxel—ABCC2—tendon—muscle cancer	0.000173	0.00605	CbGeAlD
Paclitaxel—BCL2—C-MYB transcription factor network—MYOD1—muscle cancer	0.00017	0.0126	CbGpPWpGaD
Paclitaxel—BCL2—C-MYB transcription factor network—CD34—muscle cancer	0.00017	0.0126	CbGpPWpGaD
Paclitaxel—CYP1B1—tendon—muscle cancer	0.000169	0.00593	CbGeAlD
Paclitaxel—BCL2—DNA Damage Response (only ATM dependent)—TP73—muscle cancer	0.000169	0.0125	CbGpPWpGaD
Paclitaxel—BCL2—TP53 Network—MDM2—muscle cancer	0.000168	0.0124	CbGpPWpGaD
Paclitaxel—CYP2C8—renal system—muscle cancer	0.000166	0.00581	CbGeAlD
Paclitaxel—BCL2—Overview of nanoparticle effects—PTGS2—muscle cancer	0.000162	0.012	CbGpPWpGaD
Paclitaxel—CYP19A1—head—muscle cancer	0.000155	0.00543	CbGeAlD
Paclitaxel—ABCC1—tendon—muscle cancer	0.000152	0.00533	CbGeAlD
Paclitaxel—CYP19A1—testis—muscle cancer	0.00015	0.00525	CbGeAlD
Paclitaxel—CYP3A5—renal system—muscle cancer	0.00015	0.00525	CbGeAlD
Paclitaxel—BCL2—Direct p53 effectors—PMS2—muscle cancer	0.000149	0.011	CbGpPWpGaD
Paclitaxel—MAP2—LKB1 signaling events—TP53—muscle cancer	0.000145	0.0108	CbGpPWpGaD
Paclitaxel—CYP1B1—head—muscle cancer	0.000145	0.00508	CbGeAlD
Paclitaxel—ABCC2—testis—muscle cancer	0.000143	0.00501	CbGeAlD
Paclitaxel—ABCC1—vagina—muscle cancer	0.000141	0.00495	CbGeAlD
Paclitaxel—CYP1B1—testis—muscle cancer	0.00014	0.00491	CbGeAlD
Paclitaxel—MAPT—Kit receptor signaling pathway—KIT—muscle cancer	0.00014	0.0104	CbGpPWpGaD
Paclitaxel—BCL2—Direct p53 effectors—TP73—muscle cancer	0.000138	0.0102	CbGpPWpGaD
Paclitaxel—TUBB2B—Metabolism of proteins—TIMM10—muscle cancer	0.000137	0.0102	CbGpPWpGaD
Paclitaxel—TUBB6—Metabolism of proteins—TIMM10—muscle cancer	0.000137	0.0102	CbGpPWpGaD
Paclitaxel—CYP19A1—FSH signaling pathway—FOXO1—muscle cancer	0.000133	0.00985	CbGpPWpGaD
Paclitaxel—MAPT—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	0.000133	0.00984	CbGpPWpGaD
Paclitaxel—TUBB3—Metabolism of proteins—TIMM10—muscle cancer	0.000133	0.00983	CbGpPWpGaD
Paclitaxel—TUBB2A—Metabolism of proteins—TIMM10—muscle cancer	0.000129	0.00952	CbGpPWpGaD
Paclitaxel—ABCC1—testis—muscle cancer	0.000126	0.00441	CbGeAlD
Paclitaxel—TUBB1—Metabolism of proteins—TIMM10—muscle cancer	0.000126	0.00931	CbGpPWpGaD
Paclitaxel—ABCG2—bone marrow—muscle cancer	0.000122	0.00427	CbGeAlD
Paclitaxel—MAPT—Copper homeostasis—MDM2—muscle cancer	0.000122	0.00903	CbGpPWpGaD
Paclitaxel—CYP1B1—Melatonin metabolism and effects—FOXO1—muscle cancer	0.000121	0.00896	CbGpPWpGaD
Paclitaxel—CYP2C8—vagina—muscle cancer	0.00012	0.00421	CbGeAlD
Paclitaxel—MAPT—BDNF signaling pathway—CNR1—muscle cancer	0.00012	0.00885	CbGpPWpGaD
Paclitaxel—BCL2—Direct p53 effectors—TP63—muscle cancer	0.000119	0.0088	CbGpPWpGaD
Paclitaxel—ABCC2—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	0.000117	0.00866	CbGpPWpGaD
Paclitaxel—ABCG2—vagina—muscle cancer	0.000117	0.00409	CbGeAlD
Paclitaxel—TUBB4A—Metabolism of proteins—TIMM10—muscle cancer	0.000113	0.00836	CbGpPWpGaD
Paclitaxel—CYP3A4—renal system—muscle cancer	0.000112	0.00394	CbGeAlD
Paclitaxel—CYP3A5—vagina—muscle cancer	0.000108	0.0038	CbGeAlD
Paclitaxel—BCL2—Senescence and Autophagy in Cancer—HMGA1—muscle cancer	0.000107	0.00796	CbGpPWpGaD
Paclitaxel—CYP2C8—testis—muscle cancer	0.000107	0.00376	CbGeAlD
Paclitaxel—ABCB1—embryo—muscle cancer	0.000105	0.00368	CbGeAlD
Paclitaxel—ABCG2—testis—muscle cancer	0.000104	0.00365	CbGeAlD
Paclitaxel—TUBB4B—Metabolism of proteins—TIMM10—muscle cancer	0.000103	0.00765	CbGpPWpGaD
Paclitaxel—ABCC1—S1P1 pathway—PTGS2—muscle cancer	0.000101	0.00751	CbGpPWpGaD
Paclitaxel—MAPT—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	9.71e-05	0.0072	CbGpPWpGaD
Paclitaxel—BCL2—Signaling events mediated by Stem cell factor receptor (c-Kit)—KIT—muscle cancer	9.67e-05	0.00716	CbGpPWpGaD
Paclitaxel—BCL2—TP53 Network—TP53—muscle cancer	9.62e-05	0.00713	CbGpPWpGaD
Paclitaxel—BCL2—Apoptosis—IGF2—muscle cancer	9.25e-05	0.00685	CbGpPWpGaD
Paclitaxel—BCL2—Kit receptor signaling pathway—KIT—muscle cancer	8.6e-05	0.00637	CbGpPWpGaD
Paclitaxel—BCL2—Integrated Cancer Pathway—MDM2—muscle cancer	8.57e-05	0.00635	CbGpPWpGaD
Paclitaxel—BCL2—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	8.17e-05	0.00605	CbGpPWpGaD
Paclitaxel—MAPT—LKB1 signaling events—TP53—muscle cancer	8.14e-05	0.00603	CbGpPWpGaD
Paclitaxel—ABCC1—S1P1 pathway—VEGFA—muscle cancer	7.99e-05	0.00592	CbGpPWpGaD
Paclitaxel—ABCB1—renal system—muscle cancer	7.95e-05	0.00279	CbGeAlD
Paclitaxel—BCL2—Activation of BH3-only proteins—TP53—muscle cancer	7.73e-05	0.00572	CbGpPWpGaD
Paclitaxel—CYP3A5—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	7.28e-05	0.0054	CbGpPWpGaD
Paclitaxel—MAPT—Copper homeostasis—TP53—muscle cancer	6.99e-05	0.00518	CbGpPWpGaD
Paclitaxel—MAP2—SIDS Susceptibility Pathways—VEGFA—muscle cancer	6.86e-05	0.00508	CbGpPWpGaD
Paclitaxel—TUBB2A—Signaling events mediated by HDAC Class III—TP53—muscle cancer	6.62e-05	0.00491	CbGpPWpGaD
Paclitaxel—BCL2—C-MYB transcription factor network—KIT—muscle cancer	6.49e-05	0.0048	CbGpPWpGaD
Paclitaxel—NR1I2—Generic Transcription Pathway—MED12—muscle cancer	6.35e-05	0.0047	CbGpPWpGaD
Paclitaxel—ABCB1—bone marrow—muscle cancer	6.01e-05	0.00211	CbGeAlD
Paclitaxel—BCL2—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	5.97e-05	0.00443	CbGpPWpGaD
Paclitaxel—ABCB1—vagina—muscle cancer	5.76e-05	0.00202	CbGeAlD
Paclitaxel—BCL2—Amyotrophic lateral sclerosis (ALS)—TP53—muscle cancer	5.53e-05	0.0041	CbGpPWpGaD
Paclitaxel—BCL2—Intrinsic Pathway for Apoptosis—TP53—muscle cancer	5.53e-05	0.0041	CbGpPWpGaD
Paclitaxel—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—muscle cancer	5.51e-05	0.00408	CbGpPWpGaD
Paclitaxel—ABCB1—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	5.5e-05	0.00407	CbGpPWpGaD
Paclitaxel—BCL2—Integrated Breast Cancer Pathway—FOXO1—muscle cancer	5.32e-05	0.00394	CbGpPWpGaD
Paclitaxel—ABCB1—head—muscle cancer	5.32e-05	0.00187	CbGeAlD
Paclitaxel—BCL2—C-MYB transcription factor network—CDKN2A—muscle cancer	5.27e-05	0.0039	CbGpPWpGaD
Paclitaxel—BCL2—Apoptosis—CDKN2A—muscle cancer	5.27e-05	0.0039	CbGpPWpGaD
Paclitaxel—CYP19A1—Tryptophan metabolism—MDM2—muscle cancer	5.21e-05	0.00386	CbGpPWpGaD
Paclitaxel—ABCB1—testis—muscle cancer	5.14e-05	0.0018	CbGeAlD
Paclitaxel—CYP2C9—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	5.14e-05	0.0038	CbGpPWpGaD
Paclitaxel—BCL2—Apoptosis—MDM2—muscle cancer	5.11e-05	0.00378	CbGpPWpGaD
Paclitaxel—CYP1B1—Tryptophan metabolism—MDM2—muscle cancer	5.02e-05	0.00372	CbGpPWpGaD
Paclitaxel—MAPT—Alzheimers Disease—TP53—muscle cancer	5.01e-05	0.00371	CbGpPWpGaD
Paclitaxel—Upper respiratory tract infection—Methotrexate—muscle cancer	4.95e-05	0.000643	CcSEcCtD
Paclitaxel—BCL2—Apoptosis Modulation and Signaling—CDKN2A—muscle cancer	4.94e-05	0.00366	CbGpPWpGaD
Paclitaxel—Tachycardia—Etoposide—muscle cancer	4.94e-05	0.000641	CcSEcCtD
Paclitaxel—Body temperature increased—Vincristine—muscle cancer	4.94e-05	0.000641	CcSEcCtD
Paclitaxel—Abdominal pain—Vincristine—muscle cancer	4.94e-05	0.000641	CcSEcCtD
Paclitaxel—Liver function test abnormal—Doxorubicin—muscle cancer	4.93e-05	0.00064	CcSEcCtD
Paclitaxel—BCL2—C-MYB transcription factor network—PTGS2—muscle cancer	4.92e-05	0.00365	CbGpPWpGaD
Paclitaxel—BCL2—Integrated Cancer Pathway—TP53—muscle cancer	4.92e-05	0.00364	CbGpPWpGaD
Paclitaxel—Skin disorder—Etoposide—muscle cancer	4.91e-05	0.000638	CcSEcCtD
Paclitaxel—Dry skin—Doxorubicin—muscle cancer	4.89e-05	0.000635	CcSEcCtD
Paclitaxel—Hyperhidrosis—Etoposide—muscle cancer	4.89e-05	0.000635	CcSEcCtD
Paclitaxel—Orthostatic hypotension—Doxorubicin—muscle cancer	4.88e-05	0.000633	CcSEcCtD
Paclitaxel—Abdominal pain upper—Doxorubicin—muscle cancer	4.88e-05	0.000633	CcSEcCtD
Paclitaxel—Photosensitivity reaction—Methotrexate—muscle cancer	4.86e-05	0.000632	CcSEcCtD
Paclitaxel—Hypokalaemia—Doxorubicin—muscle cancer	4.86e-05	0.000631	CcSEcCtD
Paclitaxel—CYP1B1—Aryl Hydrocarbon Receptor—PTGS2—muscle cancer	4.84e-05	0.00358	CbGpPWpGaD
Paclitaxel—Breast disorder—Doxorubicin—muscle cancer	4.82e-05	0.000627	CcSEcCtD
Paclitaxel—Anorexia—Etoposide—muscle cancer	4.82e-05	0.000626	CcSEcCtD
Paclitaxel—Toxic epidermal necrolysis—Doxorubicin—muscle cancer	4.81e-05	0.000624	CcSEcCtD
Paclitaxel—Aspartate aminotransferase increased—Doxorubicin—muscle cancer	4.81e-05	0.000624	CcSEcCtD
Paclitaxel—Diarrhoea—Dactinomycin—muscle cancer	4.78e-05	0.000621	CcSEcCtD
Paclitaxel—Pneumonia—Methotrexate—muscle cancer	4.78e-05	0.000621	CcSEcCtD
Paclitaxel—Nasopharyngitis—Doxorubicin—muscle cancer	4.77e-05	0.00062	CcSEcCtD
Paclitaxel—Infestation NOS—Methotrexate—muscle cancer	4.75e-05	0.000617	CcSEcCtD
Paclitaxel—Infestation—Methotrexate—muscle cancer	4.75e-05	0.000617	CcSEcCtD
Paclitaxel—Depression—Methotrexate—muscle cancer	4.74e-05	0.000615	CcSEcCtD
Paclitaxel—Hypotension—Etoposide—muscle cancer	4.73e-05	0.000614	CcSEcCtD
Paclitaxel—Stevens-Johnson syndrome—Methotrexate—muscle cancer	4.71e-05	0.000612	CcSEcCtD
Paclitaxel—Muscular weakness—Doxorubicin—muscle cancer	4.71e-05	0.000611	CcSEcCtD
Paclitaxel—Alanine aminotransferase increased—Doxorubicin—muscle cancer	4.71e-05	0.000611	CcSEcCtD
Paclitaxel—ABCC1—Arachidonic acid metabolism—PTGS2—muscle cancer	4.68e-05	0.00347	CbGpPWpGaD
Paclitaxel—Renal failure—Methotrexate—muscle cancer	4.67e-05	0.000607	CcSEcCtD
Paclitaxel—Abdominal distension—Doxorubicin—muscle cancer	4.65e-05	0.000603	CcSEcCtD
Paclitaxel—Stomatitis—Methotrexate—muscle cancer	4.63e-05	0.000601	CcSEcCtD
Paclitaxel—Conjunctivitis—Methotrexate—muscle cancer	4.62e-05	0.0006	CcSEcCtD
Paclitaxel—Influenza—Doxorubicin—muscle cancer	4.61e-05	0.000599	CcSEcCtD
Paclitaxel—Dysphagia—Doxorubicin—muscle cancer	4.61e-05	0.000599	CcSEcCtD
Paclitaxel—Hypersensitivity—Vincristine—muscle cancer	4.6e-05	0.000598	CcSEcCtD
Paclitaxel—Paraesthesia—Etoposide—muscle cancer	4.54e-05	0.00059	CcSEcCtD
Paclitaxel—Haematuria—Methotrexate—muscle cancer	4.53e-05	0.000588	CcSEcCtD
Paclitaxel—Pancreatitis—Doxorubicin—muscle cancer	4.52e-05	0.000587	CcSEcCtD
Paclitaxel—CYP1B1—Arachidonic acid metabolism—PTGS2—muscle cancer	4.52e-05	0.00335	CbGpPWpGaD
Paclitaxel—Dyspnoea—Etoposide—muscle cancer	4.51e-05	0.000586	CcSEcCtD
Paclitaxel—Somnolence—Etoposide—muscle cancer	4.5e-05	0.000584	CcSEcCtD
Paclitaxel—Hepatobiliary disease—Methotrexate—muscle cancer	4.49e-05	0.000584	CcSEcCtD
Paclitaxel—Epistaxis—Methotrexate—muscle cancer	4.48e-05	0.000582	CcSEcCtD
Paclitaxel—Asthenia—Vincristine—muscle cancer	4.48e-05	0.000582	CcSEcCtD
Paclitaxel—Vomiting—Dactinomycin—muscle cancer	4.44e-05	0.000577	CcSEcCtD
Paclitaxel—Bronchitis—Doxorubicin—muscle cancer	4.44e-05	0.000576	CcSEcCtD
Paclitaxel—ABCG2—HIF-2-alpha transcription factor network—VEGFA—muscle cancer	4.41e-05	0.00327	CbGpPWpGaD
Paclitaxel—Rash—Dactinomycin—muscle cancer	4.41e-05	0.000572	CcSEcCtD
Paclitaxel—BCL2—Senescence and Autophagy in Cancer—CDKN2A—muscle cancer	4.4e-05	0.00326	CbGpPWpGaD
Paclitaxel—Decreased appetite—Etoposide—muscle cancer	4.4e-05	0.000571	CcSEcCtD
Paclitaxel—Pancytopenia—Doxorubicin—muscle cancer	4.38e-05	0.000569	CcSEcCtD
Paclitaxel—Gastrointestinal disorder—Etoposide—muscle cancer	4.37e-05	0.000567	CcSEcCtD
Paclitaxel—Fatigue—Etoposide—muscle cancer	4.36e-05	0.000566	CcSEcCtD
Paclitaxel—Pain—Etoposide—muscle cancer	4.33e-05	0.000562	CcSEcCtD
Paclitaxel—Constipation—Etoposide—muscle cancer	4.33e-05	0.000562	CcSEcCtD
Paclitaxel—Neutropenia—Doxorubicin—muscle cancer	4.31e-05	0.00056	CcSEcCtD
Paclitaxel—Dysuria—Doxorubicin—muscle cancer	4.31e-05	0.00056	CcSEcCtD
Paclitaxel—MAPT—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	4.31e-05	0.00319	CbGpPWpGaD
Paclitaxel—Upper respiratory tract infection—Doxorubicin—muscle cancer	4.29e-05	0.000557	CcSEcCtD
Paclitaxel—Haemoglobin—Methotrexate—muscle cancer	4.29e-05	0.000557	CcSEcCtD
Paclitaxel—BCL2—DNA Damage Response (only ATM dependent)—CDKN2A—muscle cancer	4.28e-05	0.00317	CbGpPWpGaD
Paclitaxel—Diarrhoea—Vincristine—muscle cancer	4.27e-05	0.000555	CcSEcCtD
Paclitaxel—BCL2—Senescence and Autophagy in Cancer—MDM2—muscle cancer	4.27e-05	0.00317	CbGpPWpGaD
Paclitaxel—Haemorrhage—Methotrexate—muscle cancer	4.27e-05	0.000554	CcSEcCtD
Paclitaxel—Pollakiuria—Doxorubicin—muscle cancer	4.26e-05	0.000554	CcSEcCtD
Paclitaxel—Pharyngitis—Methotrexate—muscle cancer	4.23e-05	0.00055	CcSEcCtD
Paclitaxel—Urinary tract disorder—Methotrexate—muscle cancer	4.21e-05	0.000547	CcSEcCtD
Paclitaxel—Photosensitivity reaction—Doxorubicin—muscle cancer	4.21e-05	0.000547	CcSEcCtD
Paclitaxel—Weight increased—Doxorubicin—muscle cancer	4.2e-05	0.000545	CcSEcCtD
Paclitaxel—Urethral disorder—Methotrexate—muscle cancer	4.18e-05	0.000543	CcSEcCtD
Paclitaxel—Weight decreased—Doxorubicin—muscle cancer	4.17e-05	0.000542	CcSEcCtD
Paclitaxel—Feeling abnormal—Etoposide—muscle cancer	4.17e-05	0.000541	CcSEcCtD
Paclitaxel—Hyperglycaemia—Doxorubicin—muscle cancer	4.16e-05	0.000541	CcSEcCtD
Paclitaxel—Nausea—Dactinomycin—muscle cancer	4.15e-05	0.000539	CcSEcCtD
Paclitaxel—MAPT—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	4.15e-05	0.00307	CbGpPWpGaD
Paclitaxel—BCL2—DNA Damage Response (only ATM dependent)—MDM2—muscle cancer	4.15e-05	0.00307	CbGpPWpGaD
Paclitaxel—Pneumonia—Doxorubicin—muscle cancer	4.14e-05	0.000537	CcSEcCtD
Paclitaxel—Gastrointestinal pain—Etoposide—muscle cancer	4.14e-05	0.000537	CcSEcCtD
Paclitaxel—Dizziness—Vincristine—muscle cancer	4.13e-05	0.000536	CcSEcCtD
Paclitaxel—Infestation NOS—Doxorubicin—muscle cancer	4.11e-05	0.000534	CcSEcCtD
Paclitaxel—Infestation—Doxorubicin—muscle cancer	4.11e-05	0.000534	CcSEcCtD
Paclitaxel—Visual impairment—Methotrexate—muscle cancer	4.11e-05	0.000534	CcSEcCtD
Paclitaxel—Stevens-Johnson syndrome—Doxorubicin—muscle cancer	4.08e-05	0.00053	CcSEcCtD
Paclitaxel—Renal failure—Doxorubicin—muscle cancer	4.04e-05	0.000525	CcSEcCtD
Paclitaxel—Erythema multiforme—Methotrexate—muscle cancer	4.03e-05	0.000524	CcSEcCtD
Paclitaxel—Neuropathy peripheral—Doxorubicin—muscle cancer	4.03e-05	0.000524	CcSEcCtD
Paclitaxel—Urticaria—Etoposide—muscle cancer	4.02e-05	0.000522	CcSEcCtD
Paclitaxel—Stomatitis—Doxorubicin—muscle cancer	4.01e-05	0.000521	CcSEcCtD
Paclitaxel—Body temperature increased—Etoposide—muscle cancer	4e-05	0.000519	CcSEcCtD
Paclitaxel—Abdominal pain—Etoposide—muscle cancer	4e-05	0.000519	CcSEcCtD
Paclitaxel—Urinary tract infection—Doxorubicin—muscle cancer	4e-05	0.000519	CcSEcCtD
Paclitaxel—Conjunctivitis—Doxorubicin—muscle cancer	4e-05	0.000519	CcSEcCtD
Paclitaxel—Eye disorder—Methotrexate—muscle cancer	3.99e-05	0.000518	CcSEcCtD
Paclitaxel—Tinnitus—Methotrexate—muscle cancer	3.98e-05	0.000516	CcSEcCtD
Paclitaxel—Vomiting—Vincristine—muscle cancer	3.97e-05	0.000516	CcSEcCtD
Paclitaxel—Cardiac disorder—Methotrexate—muscle cancer	3.96e-05	0.000514	CcSEcCtD
Paclitaxel—Rash—Vincristine—muscle cancer	3.94e-05	0.000511	CcSEcCtD
Paclitaxel—Dermatitis—Vincristine—muscle cancer	3.93e-05	0.000511	CcSEcCtD
Paclitaxel—Haematuria—Doxorubicin—muscle cancer	3.92e-05	0.000509	CcSEcCtD
Paclitaxel—Headache—Vincristine—muscle cancer	3.91e-05	0.000508	CcSEcCtD
Paclitaxel—Hepatobiliary disease—Doxorubicin—muscle cancer	3.89e-05	0.000505	CcSEcCtD
Paclitaxel—Epistaxis—Doxorubicin—muscle cancer	3.88e-05	0.000504	CcSEcCtD
Paclitaxel—Angiopathy—Methotrexate—muscle cancer	3.87e-05	0.000503	CcSEcCtD
Paclitaxel—Sinusitis—Doxorubicin—muscle cancer	3.86e-05	0.000501	CcSEcCtD
Paclitaxel—Immune system disorder—Methotrexate—muscle cancer	3.85e-05	0.0005	CcSEcCtD
Paclitaxel—Mediastinal disorder—Methotrexate—muscle cancer	3.84e-05	0.000499	CcSEcCtD
Paclitaxel—Chills—Methotrexate—muscle cancer	3.83e-05	0.000497	CcSEcCtD
Paclitaxel—CYP1B1—Aryl Hydrocarbon Receptor—VEGFA—muscle cancer	3.81e-05	0.00282	CbGpPWpGaD
Paclitaxel—Alopecia—Methotrexate—muscle cancer	3.77e-05	0.000489	CcSEcCtD
Paclitaxel—Bradycardia—Doxorubicin—muscle cancer	3.76e-05	0.000488	CcSEcCtD
Paclitaxel—TUBB—Cell Cycle, Mitotic—BUB1B—muscle cancer	3.75e-05	0.00278	CbGpPWpGaD
Paclitaxel—Mental disorder—Methotrexate—muscle cancer	3.74e-05	0.000485	CcSEcCtD
Paclitaxel—Hypersensitivity—Etoposide—muscle cancer	3.73e-05	0.000484	CcSEcCtD
Paclitaxel—Erythema—Methotrexate—muscle cancer	3.71e-05	0.000482	CcSEcCtD
Paclitaxel—Malnutrition—Methotrexate—muscle cancer	3.71e-05	0.000482	CcSEcCtD
Paclitaxel—Haemoglobin—Doxorubicin—muscle cancer	3.71e-05	0.000482	CcSEcCtD
Paclitaxel—Nausea—Vincristine—muscle cancer	3.71e-05	0.000482	CcSEcCtD
Paclitaxel—Rhinitis—Doxorubicin—muscle cancer	3.7e-05	0.000481	CcSEcCtD
Paclitaxel—Haemorrhage—Doxorubicin—muscle cancer	3.69e-05	0.00048	CcSEcCtD
Paclitaxel—Hypoaesthesia—Doxorubicin—muscle cancer	3.67e-05	0.000477	CcSEcCtD
Paclitaxel—Pharyngitis—Doxorubicin—muscle cancer	3.67e-05	0.000476	CcSEcCtD
Paclitaxel—Urinary tract disorder—Doxorubicin—muscle cancer	3.65e-05	0.000474	CcSEcCtD
Paclitaxel—Oedema peripheral—Doxorubicin—muscle cancer	3.64e-05	0.000472	CcSEcCtD
Paclitaxel—Dysgeusia—Methotrexate—muscle cancer	3.64e-05	0.000472	CcSEcCtD
Paclitaxel—Asthenia—Etoposide—muscle cancer	3.63e-05	0.000471	CcSEcCtD
Paclitaxel—Connective tissue disorder—Doxorubicin—muscle cancer	3.63e-05	0.000471	CcSEcCtD
Paclitaxel—Urethral disorder—Doxorubicin—muscle cancer	3.62e-05	0.00047	CcSEcCtD
Paclitaxel—Back pain—Methotrexate—muscle cancer	3.59e-05	0.000466	CcSEcCtD
Paclitaxel—Pruritus—Etoposide—muscle cancer	3.58e-05	0.000465	CcSEcCtD
Paclitaxel—Visual impairment—Doxorubicin—muscle cancer	3.56e-05	0.000462	CcSEcCtD
Paclitaxel—Vision blurred—Methotrexate—muscle cancer	3.5e-05	0.000454	CcSEcCtD
Paclitaxel—Erythema multiforme—Doxorubicin—muscle cancer	3.49e-05	0.000453	CcSEcCtD
Paclitaxel—Diarrhoea—Etoposide—muscle cancer	3.46e-05	0.00045	CcSEcCtD
Paclitaxel—Eye disorder—Doxorubicin—muscle cancer	3.45e-05	0.000448	CcSEcCtD
Paclitaxel—Ill-defined disorder—Methotrexate—muscle cancer	3.45e-05	0.000447	CcSEcCtD
Paclitaxel—Tinnitus—Doxorubicin—muscle cancer	3.44e-05	0.000447	CcSEcCtD
Paclitaxel—Anaemia—Methotrexate—muscle cancer	3.43e-05	0.000446	CcSEcCtD
Paclitaxel—Cardiac disorder—Doxorubicin—muscle cancer	3.43e-05	0.000445	CcSEcCtD
Paclitaxel—Flushing—Doxorubicin—muscle cancer	3.43e-05	0.000445	CcSEcCtD
Paclitaxel—ABCG2—Fluoropyrimidine Activity—TP53—muscle cancer	3.42e-05	0.00253	CbGpPWpGaD
Paclitaxel—BCL2—Direct p53 effectors—MDM2—muscle cancer	3.39e-05	0.00251	CbGpPWpGaD
Paclitaxel—CYP3A4—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	3.39e-05	0.00251	CbGpPWpGaD
Paclitaxel—CYP19A1—Integrated Breast Cancer Pathway—FOXO1—muscle cancer	3.35e-05	0.00248	CbGpPWpGaD
Paclitaxel—Angiopathy—Doxorubicin—muscle cancer	3.35e-05	0.000435	CcSEcCtD
Paclitaxel—TUBB—Cell Cycle—BUB1B—muscle cancer	3.35e-05	0.00248	CbGpPWpGaD
Paclitaxel—Malaise—Methotrexate—muscle cancer	3.35e-05	0.000435	CcSEcCtD
Paclitaxel—Dizziness—Etoposide—muscle cancer	3.35e-05	0.000434	CcSEcCtD
Paclitaxel—Immune system disorder—Doxorubicin—muscle cancer	3.34e-05	0.000433	CcSEcCtD
Paclitaxel—Vertigo—Methotrexate—muscle cancer	3.34e-05	0.000433	CcSEcCtD
Paclitaxel—Mediastinal disorder—Doxorubicin—muscle cancer	3.33e-05	0.000432	CcSEcCtD
Paclitaxel—Leukopenia—Methotrexate—muscle cancer	3.32e-05	0.000432	CcSEcCtD
Paclitaxel—Chills—Doxorubicin—muscle cancer	3.31e-05	0.00043	CcSEcCtD
Paclitaxel—Arrhythmia—Doxorubicin—muscle cancer	3.3e-05	0.000428	CcSEcCtD
Paclitaxel—MAPT—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	3.27e-05	0.00242	CbGpPWpGaD
Paclitaxel—Alopecia—Doxorubicin—muscle cancer	3.26e-05	0.000424	CcSEcCtD
Paclitaxel—Cough—Methotrexate—muscle cancer	3.24e-05	0.000421	CcSEcCtD
Paclitaxel—Mental disorder—Doxorubicin—muscle cancer	3.24e-05	0.00042	CcSEcCtD
Paclitaxel—Convulsion—Methotrexate—muscle cancer	3.22e-05	0.000418	CcSEcCtD
Paclitaxel—Vomiting—Etoposide—muscle cancer	3.22e-05	0.000418	CcSEcCtD
Paclitaxel—Malnutrition—Doxorubicin—muscle cancer	3.22e-05	0.000418	CcSEcCtD
Paclitaxel—Erythema—Doxorubicin—muscle cancer	3.22e-05	0.000418	CcSEcCtD
Paclitaxel—BCL2—Integrated Breast Cancer Pathway—MDM2—muscle cancer	3.19e-05	0.00237	CbGpPWpGaD
Paclitaxel—Rash—Etoposide—muscle cancer	3.19e-05	0.000414	CcSEcCtD
Paclitaxel—Dermatitis—Etoposide—muscle cancer	3.19e-05	0.000414	CcSEcCtD
Paclitaxel—Headache—Etoposide—muscle cancer	3.17e-05	0.000412	CcSEcCtD
Paclitaxel—Flatulence—Doxorubicin—muscle cancer	3.17e-05	0.000411	CcSEcCtD
Paclitaxel—Arthralgia—Methotrexate—muscle cancer	3.16e-05	0.00041	CcSEcCtD
Paclitaxel—Myalgia—Methotrexate—muscle cancer	3.16e-05	0.00041	CcSEcCtD
Paclitaxel—Chest pain—Methotrexate—muscle cancer	3.16e-05	0.00041	CcSEcCtD
Paclitaxel—Tension—Doxorubicin—muscle cancer	3.15e-05	0.00041	CcSEcCtD
Paclitaxel—Dysgeusia—Doxorubicin—muscle cancer	3.15e-05	0.000409	CcSEcCtD
Paclitaxel—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	3.14e-05	0.000408	CcSEcCtD
Paclitaxel—Discomfort—Methotrexate—muscle cancer	3.12e-05	0.000406	CcSEcCtD
Paclitaxel—Nervousness—Doxorubicin—muscle cancer	3.12e-05	0.000406	CcSEcCtD
Paclitaxel—Back pain—Doxorubicin—muscle cancer	3.11e-05	0.000404	CcSEcCtD
Paclitaxel—TUBB4A—Cell Cycle, Mitotic—BUB1B—muscle cancer	3.1e-05	0.0023	CbGpPWpGaD
Paclitaxel—Muscle spasms—Doxorubicin—muscle cancer	3.09e-05	0.000401	CcSEcCtD
Paclitaxel—Confusional state—Methotrexate—muscle cancer	3.06e-05	0.000397	CcSEcCtD
Paclitaxel—NR1I2—Gene Expression—MED12—muscle cancer	3.06e-05	0.00226	CbGpPWpGaD
Paclitaxel—Anaphylactic shock—Methotrexate—muscle cancer	3.03e-05	0.000394	CcSEcCtD
Paclitaxel—Vision blurred—Doxorubicin—muscle cancer	3.03e-05	0.000393	CcSEcCtD
Paclitaxel—Infection—Methotrexate—muscle cancer	3.01e-05	0.000391	CcSEcCtD
Paclitaxel—Nausea—Etoposide—muscle cancer	3.01e-05	0.00039	CcSEcCtD
Paclitaxel—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—muscle cancer	3e-05	0.00222	CbGpPWpGaD
Paclitaxel—Ill-defined disorder—Doxorubicin—muscle cancer	2.98e-05	0.000387	CcSEcCtD
Paclitaxel—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—muscle cancer	2.98e-05	0.00221	CbGpPWpGaD
Paclitaxel—SLCO1B3—Metabolism of lipids and lipoproteins—MED12—muscle cancer	2.98e-05	0.00221	CbGpPWpGaD
Paclitaxel—Nervous system disorder—Methotrexate—muscle cancer	2.97e-05	0.000386	CcSEcCtD
Paclitaxel—Anaemia—Doxorubicin—muscle cancer	2.97e-05	0.000386	CcSEcCtD
Paclitaxel—Thrombocytopenia—Methotrexate—muscle cancer	2.97e-05	0.000385	CcSEcCtD
Paclitaxel—Agitation—Doxorubicin—muscle cancer	2.95e-05	0.000384	CcSEcCtD
Paclitaxel—Skin disorder—Methotrexate—muscle cancer	2.94e-05	0.000382	CcSEcCtD
Paclitaxel—BCL2—Apoptosis—TP53—muscle cancer	2.93e-05	0.00217	CbGpPWpGaD
Paclitaxel—Hyperhidrosis—Methotrexate—muscle cancer	2.93e-05	0.00038	CcSEcCtD
Paclitaxel—MAPT—Apoptosis—TP53—muscle cancer	2.92e-05	0.00216	CbGpPWpGaD
Paclitaxel—Malaise—Doxorubicin—muscle cancer	2.9e-05	0.000377	CcSEcCtD
Paclitaxel—Vertigo—Doxorubicin—muscle cancer	2.89e-05	0.000375	CcSEcCtD
Paclitaxel—Anorexia—Methotrexate—muscle cancer	2.89e-05	0.000375	CcSEcCtD
Paclitaxel—Syncope—Doxorubicin—muscle cancer	2.88e-05	0.000374	CcSEcCtD
Paclitaxel—Leukopenia—Doxorubicin—muscle cancer	2.88e-05	0.000374	CcSEcCtD
Paclitaxel—Palpitations—Doxorubicin—muscle cancer	2.84e-05	0.000369	CcSEcCtD
Paclitaxel—TUBB4B—Cell Cycle, Mitotic—BUB1B—muscle cancer	2.84e-05	0.0021	CbGpPWpGaD
Paclitaxel—Hypotension—Methotrexate—muscle cancer	2.83e-05	0.000368	CcSEcCtD
Paclitaxel—Loss of consciousness—Doxorubicin—muscle cancer	2.83e-05	0.000367	CcSEcCtD
Paclitaxel—Cough—Doxorubicin—muscle cancer	2.81e-05	0.000364	CcSEcCtD
Paclitaxel—ABCB11—Metabolism of lipids and lipoproteins—MED12—muscle cancer	2.8e-05	0.00208	CbGpPWpGaD
Paclitaxel—Convulsion—Doxorubicin—muscle cancer	2.79e-05	0.000362	CcSEcCtD
Paclitaxel—TUBB4A—Cell Cycle—BUB1B—muscle cancer	2.78e-05	0.00206	CbGpPWpGaD
Paclitaxel—Hypertension—Doxorubicin—muscle cancer	2.78e-05	0.00036	CcSEcCtD
Paclitaxel—Musculoskeletal discomfort—Methotrexate—muscle cancer	2.76e-05	0.000359	CcSEcCtD
Paclitaxel—BCL2—Apoptosis Modulation and Signaling—TP53—muscle cancer	2.75e-05	0.00204	CbGpPWpGaD
Paclitaxel—Insomnia—Methotrexate—muscle cancer	2.74e-05	0.000356	CcSEcCtD
Paclitaxel—MAPT—MAPK Signaling Pathway—TP53—muscle cancer	2.74e-05	0.00203	CbGpPWpGaD
Paclitaxel—Arthralgia—Doxorubicin—muscle cancer	2.74e-05	0.000355	CcSEcCtD
Paclitaxel—Myalgia—Doxorubicin—muscle cancer	2.74e-05	0.000355	CcSEcCtD
Paclitaxel—Chest pain—Doxorubicin—muscle cancer	2.74e-05	0.000355	CcSEcCtD
Paclitaxel—Anxiety—Doxorubicin—muscle cancer	2.73e-05	0.000354	CcSEcCtD
Paclitaxel—Paraesthesia—Methotrexate—muscle cancer	2.72e-05	0.000353	CcSEcCtD
Paclitaxel—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	2.72e-05	0.000353	CcSEcCtD
Paclitaxel—Discomfort—Doxorubicin—muscle cancer	2.7e-05	0.000351	CcSEcCtD
Paclitaxel—Dyspnoea—Methotrexate—muscle cancer	2.7e-05	0.000351	CcSEcCtD
Paclitaxel—Somnolence—Methotrexate—muscle cancer	2.69e-05	0.00035	CcSEcCtD
Paclitaxel—Dry mouth—Doxorubicin—muscle cancer	2.68e-05	0.000348	CcSEcCtD
Paclitaxel—Dyspepsia—Methotrexate—muscle cancer	2.67e-05	0.000346	CcSEcCtD
Paclitaxel—BCL2—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	2.65e-05	0.00196	CbGpPWpGaD
Paclitaxel—Confusional state—Doxorubicin—muscle cancer	2.65e-05	0.000344	CcSEcCtD
Paclitaxel—Decreased appetite—Methotrexate—muscle cancer	2.63e-05	0.000342	CcSEcCtD
Paclitaxel—Oedema—Doxorubicin—muscle cancer	2.62e-05	0.000341	CcSEcCtD
Paclitaxel—Anaphylactic shock—Doxorubicin—muscle cancer	2.62e-05	0.000341	CcSEcCtD
Paclitaxel—Gastrointestinal disorder—Methotrexate—muscle cancer	2.62e-05	0.00034	CcSEcCtD
Paclitaxel—Fatigue—Methotrexate—muscle cancer	2.61e-05	0.000339	CcSEcCtD
Paclitaxel—Infection—Doxorubicin—muscle cancer	2.61e-05	0.000339	CcSEcCtD
Paclitaxel—ABCG2—HIF-1-alpha transcription factor network—VEGFA—muscle cancer	2.6e-05	0.00192	CbGpPWpGaD
Paclitaxel—Pain—Methotrexate—muscle cancer	2.59e-05	0.000337	CcSEcCtD
Paclitaxel—Shock—Doxorubicin—muscle cancer	2.58e-05	0.000335	CcSEcCtD
Paclitaxel—Nervous system disorder—Doxorubicin—muscle cancer	2.57e-05	0.000334	CcSEcCtD
Paclitaxel—Thrombocytopenia—Doxorubicin—muscle cancer	2.57e-05	0.000334	CcSEcCtD
Paclitaxel—Tachycardia—Doxorubicin—muscle cancer	2.56e-05	0.000333	CcSEcCtD
Paclitaxel—CYP2C8—Arachidonic acid metabolism—PTGS2—muscle cancer	2.55e-05	0.00189	CbGpPWpGaD
Paclitaxel—BCL2—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	2.55e-05	0.00189	CbGpPWpGaD
Paclitaxel—Skin disorder—Doxorubicin—muscle cancer	2.55e-05	0.000331	CcSEcCtD
Paclitaxel—TUBB4B—Cell Cycle—BUB1B—muscle cancer	2.54e-05	0.00188	CbGpPWpGaD
Paclitaxel—Hyperhidrosis—Doxorubicin—muscle cancer	2.54e-05	0.000329	CcSEcCtD
Paclitaxel—Anorexia—Doxorubicin—muscle cancer	2.5e-05	0.000325	CcSEcCtD
Paclitaxel—Feeling abnormal—Methotrexate—muscle cancer	2.5e-05	0.000324	CcSEcCtD
Paclitaxel—Gastrointestinal pain—Methotrexate—muscle cancer	2.48e-05	0.000322	CcSEcCtD
Paclitaxel—MAPT—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	2.47e-05	0.00183	CbGpPWpGaD
Paclitaxel—BCL2—Innate Immune System—FOXO4—muscle cancer	2.47e-05	0.00183	CbGpPWpGaD
Paclitaxel—Hypotension—Doxorubicin—muscle cancer	2.45e-05	0.000318	CcSEcCtD
Paclitaxel—BCL2—Senescence and Autophagy in Cancer—TP53—muscle cancer	2.45e-05	0.00182	CbGpPWpGaD
Paclitaxel—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	2.44e-05	0.00181	CbGpPWpGaD
Paclitaxel—BCL2—Integrated Breast Cancer Pathway—VEGFA—muscle cancer	2.43e-05	0.0018	CbGpPWpGaD
Paclitaxel—Urticaria—Methotrexate—muscle cancer	2.41e-05	0.000313	CcSEcCtD
Paclitaxel—Abdominal pain—Methotrexate—muscle cancer	2.4e-05	0.000311	CcSEcCtD
Paclitaxel—Body temperature increased—Methotrexate—muscle cancer	2.4e-05	0.000311	CcSEcCtD
Paclitaxel—Musculoskeletal discomfort—Doxorubicin—muscle cancer	2.39e-05	0.00031	CcSEcCtD
Paclitaxel—BCL2—DNA Damage Response (only ATM dependent)—TP53—muscle cancer	2.38e-05	0.00176	CbGpPWpGaD
Paclitaxel—Insomnia—Doxorubicin—muscle cancer	2.37e-05	0.000308	CcSEcCtD
Paclitaxel—Paraesthesia—Doxorubicin—muscle cancer	2.36e-05	0.000306	CcSEcCtD
Paclitaxel—SLCO1B3—Metabolism—FH—muscle cancer	2.35e-05	0.00174	CbGpPWpGaD
Paclitaxel—Dyspnoea—Doxorubicin—muscle cancer	2.34e-05	0.000304	CcSEcCtD
Paclitaxel—Somnolence—Doxorubicin—muscle cancer	2.33e-05	0.000303	CcSEcCtD
Paclitaxel—Dyspepsia—Doxorubicin—muscle cancer	2.31e-05	0.0003	CcSEcCtD
Paclitaxel—Decreased appetite—Doxorubicin—muscle cancer	2.28e-05	0.000296	CcSEcCtD
Paclitaxel—Gastrointestinal disorder—Doxorubicin—muscle cancer	2.27e-05	0.000294	CcSEcCtD
Paclitaxel—Fatigue—Doxorubicin—muscle cancer	2.26e-05	0.000294	CcSEcCtD
Paclitaxel—TUBB6—Metabolism of proteins—IGF2—muscle cancer	2.26e-05	0.00168	CbGpPWpGaD
Paclitaxel—TUBB2B—Metabolism of proteins—IGF2—muscle cancer	2.26e-05	0.00168	CbGpPWpGaD
Paclitaxel—Constipation—Doxorubicin—muscle cancer	2.24e-05	0.000291	CcSEcCtD
Paclitaxel—Pain—Doxorubicin—muscle cancer	2.24e-05	0.000291	CcSEcCtD
Paclitaxel—Hypersensitivity—Methotrexate—muscle cancer	2.23e-05	0.00029	CcSEcCtD
Paclitaxel—ABCB11—Metabolism—FH—muscle cancer	2.21e-05	0.00164	CbGpPWpGaD
Paclitaxel—TUBB3—Metabolism of proteins—IGF2—muscle cancer	2.18e-05	0.00162	CbGpPWpGaD
Paclitaxel—Asthenia—Methotrexate—muscle cancer	2.17e-05	0.000282	CcSEcCtD
Paclitaxel—Feeling abnormal—Doxorubicin—muscle cancer	2.16e-05	0.000281	CcSEcCtD
Paclitaxel—Gastrointestinal pain—Doxorubicin—muscle cancer	2.15e-05	0.000279	CcSEcCtD
Paclitaxel—Pruritus—Methotrexate—muscle cancer	2.14e-05	0.000278	CcSEcCtD
Paclitaxel—TUBB2A—Metabolism of proteins—IGF2—muscle cancer	2.12e-05	0.00157	CbGpPWpGaD
Paclitaxel—CYP19A1—Metabolism of lipids and lipoproteins—MED12—muscle cancer	2.11e-05	0.00157	CbGpPWpGaD
Paclitaxel—BCL2—Immune System—CD34—muscle cancer	2.11e-05	0.00157	CbGpPWpGaD
Paclitaxel—ABCC1—Metabolism of lipids and lipoproteins—MED12—muscle cancer	2.11e-05	0.00156	CbGpPWpGaD
Paclitaxel—Urticaria—Doxorubicin—muscle cancer	2.08e-05	0.000271	CcSEcCtD
Paclitaxel—CYP2C9—Arachidonic acid metabolism—PTGS2—muscle cancer	2.08e-05	0.00154	CbGpPWpGaD
Paclitaxel—Abdominal pain—Doxorubicin—muscle cancer	2.07e-05	0.000269	CcSEcCtD
Paclitaxel—Body temperature increased—Doxorubicin—muscle cancer	2.07e-05	0.000269	CcSEcCtD
Paclitaxel—Diarrhoea—Methotrexate—muscle cancer	2.07e-05	0.000269	CcSEcCtD
Paclitaxel—TUBB1—Metabolism of proteins—IGF2—muscle cancer	2.07e-05	0.00153	CbGpPWpGaD
Paclitaxel—CYP1B1—Metabolism of lipids and lipoproteins—MED12—muscle cancer	2.04e-05	0.00151	CbGpPWpGaD
Paclitaxel—BCL2—Focal Adhesion—VEGFA—muscle cancer	2.02e-05	0.0015	CbGpPWpGaD
Paclitaxel—CYP19A1—Integrated Breast Cancer Pathway—MDM2—muscle cancer	2.01e-05	0.00149	CbGpPWpGaD
Paclitaxel—BCL2—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	2.01e-05	0.00149	CbGpPWpGaD
Paclitaxel—Dizziness—Methotrexate—muscle cancer	2e-05	0.00026	CcSEcCtD
Paclitaxel—BCL2—Direct p53 effectors—TP53—muscle cancer	1.95e-05	0.00144	CbGpPWpGaD
Paclitaxel—Hypersensitivity—Doxorubicin—muscle cancer	1.93e-05	0.000251	CcSEcCtD
Paclitaxel—Vomiting—Methotrexate—muscle cancer	1.93e-05	0.00025	CcSEcCtD
Paclitaxel—Rash—Methotrexate—muscle cancer	1.91e-05	0.000248	CcSEcCtD
Paclitaxel—Dermatitis—Methotrexate—muscle cancer	1.91e-05	0.000248	CcSEcCtD
Paclitaxel—Headache—Methotrexate—muscle cancer	1.9e-05	0.000247	CcSEcCtD
Paclitaxel—Asthenia—Doxorubicin—muscle cancer	1.88e-05	0.000244	CcSEcCtD
Paclitaxel—TUBB4A—Metabolism of proteins—IGF2—muscle cancer	1.86e-05	0.00138	CbGpPWpGaD
Paclitaxel—Pruritus—Doxorubicin—muscle cancer	1.86e-05	0.000241	CcSEcCtD
Paclitaxel—BCL2—Integrated Breast Cancer Pathway—TP53—muscle cancer	1.83e-05	0.00136	CbGpPWpGaD
Paclitaxel—BCL2—Innate Immune System—FOXO1—muscle cancer	1.82e-05	0.00135	CbGpPWpGaD
Paclitaxel—Nausea—Methotrexate—muscle cancer	1.8e-05	0.000234	CcSEcCtD
Paclitaxel—Diarrhoea—Doxorubicin—muscle cancer	1.8e-05	0.000233	CcSEcCtD
Paclitaxel—BCL2—Apoptosis—TP53—muscle cancer	1.8e-05	0.00133	CbGpPWpGaD
Paclitaxel—ABCB1—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	1.78e-05	0.00132	CbGpPWpGaD
Paclitaxel—Dizziness—Doxorubicin—muscle cancer	1.74e-05	0.000225	CcSEcCtD
Paclitaxel—TUBB—Cell Cycle, Mitotic—CDKN2A—muscle cancer	1.71e-05	0.00127	CbGpPWpGaD
Paclitaxel—TUBB4B—Metabolism of proteins—IGF2—muscle cancer	1.7e-05	0.00126	CbGpPWpGaD
Paclitaxel—Vomiting—Doxorubicin—muscle cancer	1.67e-05	0.000217	CcSEcCtD
Paclitaxel—CYP19A1—Metabolism—FH—muscle cancer	1.67e-05	0.00123	CbGpPWpGaD
Paclitaxel—ABCC1—Metabolism—FH—muscle cancer	1.66e-05	0.00123	CbGpPWpGaD
Paclitaxel—Rash—Doxorubicin—muscle cancer	1.65e-05	0.000215	CcSEcCtD
Paclitaxel—Dermatitis—Doxorubicin—muscle cancer	1.65e-05	0.000215	CcSEcCtD
Paclitaxel—Headache—Doxorubicin—muscle cancer	1.64e-05	0.000213	CcSEcCtD
Paclitaxel—CYP1B1—Metabolism—FH—muscle cancer	1.6e-05	0.00119	CbGpPWpGaD
Paclitaxel—Nausea—Doxorubicin—muscle cancer	1.56e-05	0.000202	CcSEcCtD
Paclitaxel—TUBB—Cell Cycle—CDKN2A—muscle cancer	1.53e-05	0.00113	CbGpPWpGaD
Paclitaxel—CYP19A1—Integrated Breast Cancer Pathway—VEGFA—muscle cancer	1.53e-05	0.00113	CbGpPWpGaD
Paclitaxel—CYP3A4—Tryptophan metabolism—MDM2—muscle cancer	1.52e-05	0.00113	CbGpPWpGaD
Paclitaxel—BCL2—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	1.52e-05	0.00113	CbGpPWpGaD
Paclitaxel—TUBB—Cell Cycle—MDM2—muscle cancer	1.48e-05	0.0011	CbGpPWpGaD
Paclitaxel—ABCG2—Metabolism—FH—muscle cancer	1.46e-05	0.00108	CbGpPWpGaD
Paclitaxel—CYP3A7—Metabolism—FH—muscle cancer	1.45e-05	0.00107	CbGpPWpGaD
Paclitaxel—BCL2—Immune System—FOXO4—muscle cancer	1.44e-05	0.00106	CbGpPWpGaD
Paclitaxel—TUBB4A—Cell Cycle, Mitotic—CDKN2A—muscle cancer	1.42e-05	0.00105	CbGpPWpGaD
Paclitaxel—ABCB1—HIF-1-alpha transcription factor network—VEGFA—muscle cancer	1.4e-05	0.00104	CbGpPWpGaD
Paclitaxel—BCL2—Innate Immune System—KIT—muscle cancer	1.39e-05	0.00103	CbGpPWpGaD
Paclitaxel—SLCO1B3—Metabolism—MED12—muscle cancer	1.33e-05	0.000982	CbGpPWpGaD
Paclitaxel—TUBB4B—Cell Cycle, Mitotic—CDKN2A—muscle cancer	1.3e-05	0.000961	CbGpPWpGaD
Paclitaxel—TUBB4A—Cell Cycle—CDKN2A—muscle cancer	1.27e-05	0.00094	CbGpPWpGaD
Paclitaxel—ABCB11—Metabolism—MED12—muscle cancer	1.25e-05	0.000925	CbGpPWpGaD
Paclitaxel—TUBB4A—Cell Cycle—MDM2—muscle cancer	1.23e-05	0.000911	CbGpPWpGaD
Paclitaxel—ABCB1—Allograft Rejection—VEGFA—muscle cancer	1.22e-05	0.000901	CbGpPWpGaD
Paclitaxel—SLCO1B3—Metabolism—ENO2—muscle cancer	1.21e-05	0.000896	CbGpPWpGaD
Paclitaxel—TUBB4B—Cell Cycle—CDKN2A—muscle cancer	1.16e-05	0.000859	CbGpPWpGaD
Paclitaxel—CYP19A1—Integrated Breast Cancer Pathway—TP53—muscle cancer	1.15e-05	0.000856	CbGpPWpGaD
Paclitaxel—CYP2C8—Metabolism of lipids and lipoproteins—MED12—muscle cancer	1.15e-05	0.000852	CbGpPWpGaD
Paclitaxel—ABCB11—Metabolism—ENO2—muscle cancer	1.14e-05	0.000843	CbGpPWpGaD
Paclitaxel—TUBB4B—Cell Cycle—MDM2—muscle cancer	1.13e-05	0.000834	CbGpPWpGaD
Paclitaxel—BCL2—Innate Immune System—MDM2—muscle cancer	1.09e-05	0.00081	CbGpPWpGaD
Paclitaxel—BCL2—Immune System—FOXO1—muscle cancer	1.06e-05	0.000786	CbGpPWpGaD
Paclitaxel—CYP3A5—Metabolism—FH—muscle cancer	1.05e-05	0.000775	CbGpPWpGaD
Paclitaxel—ABCC1—Disease—ENO2—muscle cancer	1.02e-05	0.000756	CbGpPWpGaD
Paclitaxel—SLCO1B3—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	9.45e-06	0.0007	CbGpPWpGaD
Paclitaxel—CYP19A1—Metabolism—MED12—muscle cancer	9.42e-06	0.000698	CbGpPWpGaD
Paclitaxel—ABCC1—Metabolism—MED12—muscle cancer	9.38e-06	0.000695	CbGpPWpGaD
Paclitaxel—CYP2C9—Metabolism of lipids and lipoproteins—MED12—muscle cancer	9.36e-06	0.000693	CbGpPWpGaD
Paclitaxel—ABCC1—Disease—HMGA1—muscle cancer	9.28e-06	0.000687	CbGpPWpGaD
Paclitaxel—CYP1B1—Metabolism—MED12—muscle cancer	9.07e-06	0.000672	CbGpPWpGaD
Paclitaxel—CYP2C8—Metabolism—FH—muscle cancer	9.06e-06	0.000671	CbGpPWpGaD
Paclitaxel—ABCB11—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	8.9e-06	0.000659	CbGpPWpGaD
Paclitaxel—CYP19A1—Metabolism—ENO2—muscle cancer	8.58e-06	0.000636	CbGpPWpGaD
Paclitaxel—ABCC1—Metabolism—ENO2—muscle cancer	8.55e-06	0.000633	CbGpPWpGaD
Paclitaxel—TUBB—Cell Cycle—TP53—muscle cancer	8.52e-06	0.000631	CbGpPWpGaD
Paclitaxel—ABCC1—Disease—FOXO4—muscle cancer	8.32e-06	0.000616	CbGpPWpGaD
Paclitaxel—CYP1B1—Metabolism—ENO2—muscle cancer	8.27e-06	0.000612	CbGpPWpGaD
Paclitaxel—ABCG2—Metabolism—MED12—muscle cancer	8.25e-06	0.000611	CbGpPWpGaD
Paclitaxel—CYP3A7—Metabolism—MED12—muscle cancer	8.18e-06	0.000606	CbGpPWpGaD
Paclitaxel—BCL2—Immune System—KIT—muscle cancer	8.08e-06	0.000599	CbGpPWpGaD
Paclitaxel—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	7.9e-06	0.000585	CbGpPWpGaD
Paclitaxel—ABCB1—Metabolism—FH—muscle cancer	7.89e-06	0.000585	CbGpPWpGaD
Paclitaxel—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	7.62e-06	0.000564	CbGpPWpGaD
Paclitaxel—ABCG2—Metabolism—ENO2—muscle cancer	7.52e-06	0.000557	CbGpPWpGaD
Paclitaxel—CYP3A7—Metabolism—ENO2—muscle cancer	7.45e-06	0.000552	CbGpPWpGaD
Paclitaxel—CYP2C9—Metabolism—FH—muscle cancer	7.37e-06	0.000546	CbGpPWpGaD
Paclitaxel—TUBB4A—Cell Cycle—TP53—muscle cancer	7.06e-06	0.000523	CbGpPWpGaD
Paclitaxel—CYP19A1—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	6.71e-06	0.000497	CbGpPWpGaD
Paclitaxel—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	6.68e-06	0.000495	CbGpPWpGaD
Paclitaxel—CYP1B1—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	6.47e-06	0.000479	CbGpPWpGaD
Paclitaxel—TUBB4B—Cell Cycle—TP53—muscle cancer	6.46e-06	0.000478	CbGpPWpGaD
Paclitaxel—BCL2—Immune System—MDM2—muscle cancer	6.37e-06	0.000472	CbGpPWpGaD
Paclitaxel—ABCC1—Disease—FOXO1—muscle cancer	6.14e-06	0.000455	CbGpPWpGaD
Paclitaxel—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	6e-06	0.000444	CbGpPWpGaD
Paclitaxel—CYP3A5—Metabolism—MED12—muscle cancer	5.91e-06	0.000438	CbGpPWpGaD
Paclitaxel—CYP3A5—Metabolism—ENO2—muscle cancer	5.39e-06	0.000399	CbGpPWpGaD
Paclitaxel—CYP2C8—Metabolism—MED12—muscle cancer	5.12e-06	0.000379	CbGpPWpGaD
Paclitaxel—CYP3A4—Metabolism—FH—muscle cancer	4.86e-06	0.00036	CbGpPWpGaD
Paclitaxel—ABCC1—Disease—KIT—muscle cancer	4.68e-06	0.000347	CbGpPWpGaD
Paclitaxel—CYP2C8—Metabolism—ENO2—muscle cancer	4.67e-06	0.000346	CbGpPWpGaD
Paclitaxel—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	4.53e-06	0.000336	CbGpPWpGaD
Paclitaxel—ABCB1—Metabolism—MED12—muscle cancer	4.46e-06	0.00033	CbGpPWpGaD
Paclitaxel—SLCO1B3—Metabolism—PTGS2—muscle cancer	4.21e-06	0.000312	CbGpPWpGaD
Paclitaxel—CYP2C9—Metabolism—MED12—muscle cancer	4.17e-06	0.000309	CbGpPWpGaD
Paclitaxel—ABCB1—Metabolism—ENO2—muscle cancer	4.07e-06	0.000301	CbGpPWpGaD
Paclitaxel—ABCB11—Metabolism—PTGS2—muscle cancer	3.96e-06	0.000294	CbGpPWpGaD
Paclitaxel—CYP2C9—Metabolism—ENO2—muscle cancer	3.8e-06	0.000281	CbGpPWpGaD
Paclitaxel—ABCC1—Disease—MDM2—muscle cancer	3.69e-06	0.000273	CbGpPWpGaD
Paclitaxel—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	3.65e-06	0.00027	CbGpPWpGaD
Paclitaxel—ABCC1—Disease—PTGS2—muscle cancer	3.55e-06	0.000263	CbGpPWpGaD
Paclitaxel—CYP19A1—Metabolism—PTGS2—muscle cancer	2.99e-06	0.000222	CbGpPWpGaD
Paclitaxel—ABCC1—Metabolism—PTGS2—muscle cancer	2.98e-06	0.000221	CbGpPWpGaD
Paclitaxel—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	2.97e-06	0.00022	CbGpPWpGaD
Paclitaxel—CYP1B1—Metabolism—PTGS2—muscle cancer	2.88e-06	0.000213	CbGpPWpGaD
Paclitaxel—CYP3A4—Metabolism—MED12—muscle cancer	2.75e-06	0.000204	CbGpPWpGaD
Paclitaxel—ABCG2—Metabolism—PTGS2—muscle cancer	2.62e-06	0.000194	CbGpPWpGaD
Paclitaxel—CYP3A7—Metabolism—PTGS2—muscle cancer	2.6e-06	0.000192	CbGpPWpGaD
Paclitaxel—CYP3A4—Metabolism—ENO2—muscle cancer	2.51e-06	0.000186	CbGpPWpGaD
Paclitaxel—CYP3A5—Metabolism—PTGS2—muscle cancer	1.88e-06	0.000139	CbGpPWpGaD
Paclitaxel—CYP2C8—Metabolism—PTGS2—muscle cancer	1.63e-06	0.00012	CbGpPWpGaD
Paclitaxel—ABCB1—Metabolism—PTGS2—muscle cancer	1.42e-06	0.000105	CbGpPWpGaD
Paclitaxel—CYP2C9—Metabolism—PTGS2—muscle cancer	1.32e-06	9.8e-05	CbGpPWpGaD
Paclitaxel—CYP3A4—Metabolism—PTGS2—muscle cancer	8.73e-07	6.46e-05	CbGpPWpGaD
